DNDi has various types of agreements with its partners worldwide, such as Research Services Agreements, Material Transfer Agreements, Research and License Agreements, Collaboration Agreements, Clinical Trial Agreements, Financial Agreements, etc.
Research Services Agreements regulate contractual relationship between research service providers and DNDi. Material Transfer Agreements provide access to compounds for testing. In addition to these agreements, DNDi seeks to conclude Research and License Agreements with key partners which involve a greater commitment from both parties. The core of these agreements concern IP ownership (generally owned by the partner and in some cases co-owned), and licensing clauses. Several conditions are required to ensure availability and affordability of the treatment and respect of DNDi’s IP policy objectives. As a not-for-profit and patient-needs driven organization, DNDi seeks transparency to efficiently address urgent patient needs. Therefore, the licenses should be:
- Royalty-free to ensure the lowest possible price
- Sub-licensable, or in other terms, contain the authorization to disclose the obtained information to another party in order to continue product development
- Worldwide coverage both for R&D and for manufacture
- Non-exclusive to enable third parties to enter the field (included in our most innovative agreements)
An important objective for DNDi’s agreement is limited confidentiality – to make available all information generated on the product during its development in the form of publications or databases.
-
Pharmaceuticals
-
Biotechs
-
Universities
-
University “Spin-off”
-
Research institutes
-
National Research Centres
-
NGOs/IOs
-
PDPs/PPPs
-
Hospitals
-
Ministries of Health/Governmental organizations
-
Contract Research Organizations (CROs)
Pharmaceuticals
AbbVie (formerly Abbott) (USA). Since February 2009, compounds provider for research on Chagas disease, HAT, and leishmaniasis and since 2011, formulation development and toxicology studies for helminth infections.
Projects: Flubendazole Macrofilaricide (Helminth) / Screening
Astellas Pharma Inc. (Japan), pharmaceutical company. Since June 2012, DNDi partner for drug discovery, provider of compounds for screening activities for leishmaniasis, Chagas disease, and sleeping sickness.
Projects: Screening
Astra Zeneca (Sweden). Since 2012, DNDi discovery partner. Since 2013, DNDi partner for screening.
Projects: Screening
Bristol Myers Squibb (USA). Since August 2012, DNDi partner for screening and testing in the field of visceral leishmaniasis.
Projects: Screening
CIPLA (India). Since January 2007, DNDi partner against malaria, by developing and producing the combination of the product (ASMQ) as well as file application, registration and distribution in endemic countries at cost (in the public sector). Since 2012, DNDi partner for the development and registration of two solid taste-masked LPV/r-based fixed-dose formulations, also known as the 4-in-1s.
Projects: ASMQ (Malaria) / Two 4-in-1 LPV/r-based fixed-dose combinations (Paediatric HIV)
Debiopharm (Switzerland). Material transfer agreement, beginning April 2011, for discovery activities.
Projects: Discovery
E.I du pont Nemours (USA).Since June 2012, DNDi partner for screening of compounds against helminths and kinetoplastids.
Projects: Screening
Eisai (Japan). Since September 2009, DNDi partner through collaboration and license agreement on clinical studies for Chagas disease using the E1224 compound. Eisai has the option of becoming a pharmaceutical partner for manufacturing and distribution.
Projects: Azoles E1224 & Biomarker (Chagas) / Screening
Farmanguinhos (Fiocruz) (Brazil). Since 2006, various agreements for production and distribution of ASMQ at cost in endemic countries.
Projects: ASMQ (Malaria)
GILEAD (USA). Since 2008, donation program of Ambisome® for clinical studies on VL.
GNF Novartis, Genomics Institute of the Novartis Research Foundation (USA). Since October 2009, DNDi partner for discovery phase on kinetoplastids.
Projects: Screening
GSK, Tres Cantos – Open Lab Foundation (Spain). Since May 2006, various partnerships through screening, discovery activities, and clinical trials for CL.
Projects: Screening
Humax Pharma (Colombia). Since 2011, partner for pre-clinical research on CL.
Projects: Anfoleish
Janssen Research & Development, LLC (Belgium): Since September 2013, DNDi partner for discovery and pre-clinical activities for flubendazole.
Projects: Flubendazole (Filarial diseases)
LAFEPE, Laboratorio Farmacêutico do Estado de Pernambuco (Brazil). Since June 2008, Preclinical agreement and collaboration agreement for Chagas disease: to manufacture the paediatric formulation of benznidazole.
Projects: Paediatric Benznidazole (Chagas)
Merck & Co. (USA). Since 2008, Merck granted access to compounds through a non-exclusive, worldwide license, for research on NTDs.
Projects: Screening
Novartis Centre de Recherche Santé Animale S.A. (Switzerland). Since November 2013, DNDi partner for screening and lead optimization activities on filarial diseases.
Projects: Screening & Lead Optimization
Paladin Labs (Canada). Since 2009, Paladin Labs provides miltefosine for clinical studies on VL in Eastern Africa.
Projects: New VL treatments – Africa
Pfizer Limited (UK). Since 2004: material transfer agreement to provide amodiaquine for ASAQ; 2009, research and license agreement to access compound libraries. Since 2012, DNDi lead optimization partner (access to series identified out of a Pfizer screening).
Projects: Screening & Lead Optimization
Sanofi and affiliates (France). Since 2004, DNDi partner through manufacture, registration, and distribution partner for ASAQ in endemic countries. Since January 2011, R&D license agreement to allow research and development on various NTDs, aiming to provide affordable treatments in endemic countries of low -middle income economies and Latin America. More specifically, Sanofi partners with DNDi on Fexinidazole clinical studies for HAT. Since November 2012, DNDi partner for capacity strengthening and technology transfer to Tanzania in the field of malaria.
Projects: ASAQ (Malaria) / Fexinidazole (HAT) / Screening
TAKEDA Pharmaceutical Company Limited (Japan). Since June 2013, DNDi partner for screening.
Projects: Screening
Zenufa Laboratories Ltd (Tanzania). Since March 2011, recipient of DNDi’s technology transfer of ASAQ. Partner for manufacture and distribution.
Projects: ASAQ (Malaria)
Anacor (USA). Since December 2007, DNDi partner through research collaboration and license agreement to provide compounds of the oxaborole class for research on HAT, VL-CL, and Chagas disease.
Projects: Oxaborole backup (HAT) / Oxaborole SCYX-7158 (HAT) / Screening
Celgene (USA). Material transfer agreement since 2011 for screening on HAT, Chagas disease, and Leishmaniasis. Since 2014, DNDi partner for screening.
Projects: Screening
Genzyme, biotechnology company part of the Sanofi group (USA). Material transfer for research and development on HAT, Chagas disease, and Leishmaniasis.
Evolva (Switzerland). Since 2008, DNDi partner in discovery for kinetoplastids.
Projects: Discovery
iThemba (South Africa). Since 2012, lead optimization partner.
Projects: Lead Optimization
Polytherics (UK). Since October 2006, DNDi partner on formulation of amphotericin B, in collaboration with Imperial College.
Scynexis (USA). Since December 2005, DNDi partner through screening and material transfer for research and development on kinetoplastids.
Projects: Oxaborole SCXY-7158 (HAT) / Lead Optimization
Sequella, Inc (USA). Since February 2015, material transfer agreement for screening on kinetoplastids.
Projects: Screening
Vertex (USA). Since January 2010, DNDi partner through material transfer agreement for R&D, in the field of kinetoplastids.
Projects: Screening
Addis Ababa University (Ethiopia), Leishmaniasis East Africa Platform (LEAP) partner. Since April 2005, clinical trial partner for leishmaniasis.
Projects: Fexinidazole (VL) / HIV/VL / New VL treatments (Africa) / SSG&PM (VL in Africa)
Antwerp University, Laboratory of Microbiology, Parasitology and Hygiene (LMPH) (Belgium). Since June 2006, DNDi partner for screening and discovery activities.
Projects: Lead Optimization
Baylor College of Medicine (USA). Since August 2013, works with DNDi on study of seroprevalence of Chagas in USA.
Bonn University Hospital, Institute of Medical Microbiology, Immunology and Parasitology (DE). Since December 2012, DNDi partner for testing of repurposed compounds in animal models for filarial infections.
Brasilia University (Brazil). DNDi partner for clinical trials for VL.
Projects: New VL treatments (Latin America)
Dundee University, Research and Innovation Services (UK). Since 2004, DNDi partner through research and development license agreement on HAT, and Leishmaniasis.
Projects: Screening
FAPUNIFESP, Fundaçao de Apoio Universidade Federale de Sao Paolo (Brazil). Since March 2009, DNDi partner in the field of Chagas disease.
Gondar University Hospital (Ethiopia). Leishmaniasis East Africa Partner (LEAP) partner. Since March 2005, DNDi partner for clinical trials for VL.
Projects: HIV/VL / New VL treatments (Africa)
Imperial College (UK). Since October 2006, DNDi partner on formulation of amphotericin B with Polytherics.
London School of Pharmacy (UK). Since October 2006, partner on formulation of amphotericin B, in collaboration with Imperial College.
LSHTM, London School of Hygiene and Tropical Medecine (UK). Since January 2005, DNDi partner for screening, clinical trials and discovery. Since November 2013, works with DNDi on comparison of benznidazole and posaconazole for Chagas disease.
Projects: HIV/VL / Lead Optimization / New VL treatments (Africa) / New VL treatments (Asia) / Nitroimidazole backup (VL) / VL-2098 / Biomarkers (Chagas) / Screening & Lead Optimization
Makerere University and Amudat Hospital (Uganda). Since November 2008, DNDi partner for clinical trials for VL.
Projects: New VL treatments (Africa)
McGill University (Canada). Since January 2014, DNDi partner for pre-clinical work on Chagas disease.
Projects: Biomarkers (Chagas)
Michigan State University (USA). Since 2011, DNDi pre-clinical research partner for helminth infections.
Projects: Flubendazole Macrofilaricide (Filarial diseases)
Monash University, Centre for Drug Candidate Optimization (Australia). Since July 2008, DNDi partner through a technical agreement for Chagas disease.
Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization
Murdoch University, School of Veterinary and Biomedical Science (Australia). Since August 2006, technical agreement, and since July 200, R&D agreement on Chagas disease.
Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization
Pace University (USA). Since April 2007, DNDi partner for pre-clinical studies in the field of HAT.
Projects: Nitroimidazole backup (HAT) / Oxaborole backup (HAT) / Lead Optimization
Stellenbosch University (South Africa). Since November 2012, DNDi partner for clinical trials in the field of HIV/TB.
Projects: “Superboosting” – TB/HIV
UCSF, University of California, San Francisco (USA). Since January 2011, DNDi partner for pre-clinical studies on Chagas disease. Since April 2014, works with DNDi on clinical analysis for the RTV Superbooster project.
Projects: K777 (Chagas) / RTV Superbooster for HIV/TB co-infection (Paediatric HIV)
University of Antoquia, PECET – Programme for the study and control of tropical diseases (Colombia). Since 2011, DNDi partner on pre-clinical studies for CL.
Projects: Anfoleish
University of Auckland (New Zealand). In 2009, DNDi partner for HAT, and since 2010, partner on VL.
Projects: SCYX-2035811 / Nitroimidazole backup (VL) / VL-2098 / Lead Optimization
Universidade Estadual de Campinas UNICAMP (Brazil). Since July 2013, DNDi partner for lead optimization in the field of Chagas disease and leishmaniasis.
Project: Lead Optimization
Universidad Mayor de San Simon (Bolivia). DNDi partner for clinical trials for Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas)
University of North Carolina, Office of Technology Development (USA). Since 2007, DNDi partner through information sharing and discovery for NTDs.
Universidade Ouro Preto (Brazil). Since April 2005, DNDi partner in the field of Chagas disease through discovery and R&D agreement.
Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization
University of Oxford, Worldwide Antimalarial Drug Resistance Network (UK). Since October 2009, DNDi partner through data collection on malaria.
Projects: ASAQ (Malaria) / ASMQ (Malaria)
University Sains (Malaysia). Since April 2004, DNDi partner on malaria.
Projects: ASAQ (Malaria) / ASMQ (Malaria)
Utrecht University, (The Netherlands). Since 2009, DNDi partner for clinical trials for VL.
Projects: VL-0208 (Africa)
Epichem, product and service provider in synthetic and medicinal chemistry to the drug discovery and pharmaceutical industries (Australia). Since 2008, provides medicinal chemistry lead optimization for series on kinetoplastids.
Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Lead Optimization
Eskitis, The Eskitis Institute for Cell and Molecular Therapies. Griffith University (Australia). Since 2009, partner on drug discovery for HAT. Setup and validation of in vitro assays.
Projects: Lead Optimization
Broad Institute, MIT and Harvard (USA). Since September 2010, DNDi partner through discovery activity for Chagas disease.
CRESIB, Centre de Recerca en Salut Internacional de Barcelona (Spain). Since September 2010, DNDi partner for the clinical phase for Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas)
FIPEC: Fundacion Para el Estudio de las Infecciones Parasitarias y enfermedad de Chagas (Argentina). Since 2010, DNDi partner on clinical studies for Chagas disease.
Georges Institute for International Health (Australia). Since May 2009, DNDi partner through research.
IMEA Consulting France : Institut de Médecine et d’Epidémiologie Appliquée, Département de Santé Tropicale (France). Since January 2010, DNDi partner for clinical phase of ASAQ (malaria).
IEND, Institute of Endemic Disease, Khartoum University (Sudan), Leishmaniasis East Africa Platform (LEAP). Since December 2004, DNDi partner for clinical trials for VL patients.
Projects: Fexinidazole (VL) / VL-0208 / SSG&PM (VL in Africa)
Ifakara Health Institute (Tanzania). Since June 2012, DNDi partner for clinical studies on ASMQ against malaria.
Projects: ASMQ (Malaria)
IRD, Institut de Recherche pour le Développement (France). Since 2007, various partnerships on VL and currently partner for clinical trials of ASAQ (malaria).
Projects: ASAQ (Malaria)
Institut Pasteur (France). Since December 2008, discovery and screening partner for leishmaniasis.
Institut Pasteur Korea (Korea). Since April 2008, DNDi partner on Chagas disease and leishmaniasis for high throughput screening and discovery activities.
Projects: Fenarimol series (Chagas) / Nitroimidazole (Chagas) / Screening & Lead Optimization
Institut René Rachou IdP (Brazil). Since October 2007, DNDi partner for pre-clinical studies for VL.
Projects: New VL treatments (Latin America)
Institute of Tropical Medicine (Belgium). Since September 2006, DNDi partner for HAT, malaria and since May 2011, partner for clinical trials on VL, and HIV co-infected patients). Since September 2012, DNDi partner and supplier of reagents and accessories for diagnostic tests in the clinical phase of fexinidazole against sleeping sickness.
Projects: VL-0208 / HIV/VL
KEMRI, Kenya Medical Research Institute (Kenya). Since January 2005, various partnerships for clinical trials of malaria (ASAQ and ASMQ) as well as VL.
Projects: ASAQ (Malaria) / ASMQ (Malaria) / Fexinidazole (VL) / VL-0208 / SSG&PM (VL in Africa)
KIT, Koninklijk Instituut voor de Tropen (Netherlands). Since January 2014, DNDi partner for PD analysis on the fexinidazole VL study.
Projects: Fexinidazole (VL)
Medical Research Council (MRC), publicly-funded organization (UK). Since May 2012, DNDi partner for clinical trial in the field of paediatric HIV.
Projects: Two 4-in-1 LPV/r-based fixed-dose combinations (Paediatric HIV)
Northwick Park Institute for Medical Research (NPIMR) (UK). Since 2012, partner for screening for helminth infections.
Pasteur Institute of Iran (Iran). Since 2012, partner for pre-clinical research for CL.
Seattle Biomedical Research Institute (USA). Since October 2008, DNDi partner for discovery on NTDs.
Swiss Tropical and Public Health Institute (Switzerland). Since 2006, various partnerships through discovery, screening (kinetolastids), and clinical trials for HAT, leishmaniasis.
Projects: Fexinidazole (HAT) / NECT (HAT) / Nitromidazole backup (HAT)
Texas Biomedical Research,private research institute (USA). Since October 2012, DNDi partner for pre-clinical research in the field of Chagas disease.Evaluation of potential indicators of parasitological cure following drug therapy.
Projects: Azoles E1224 & Biomarker (Chagas)
University of Georgia Research Foundation (USA). Since October 2012, DNDi partner for pre-clinical research in the field of Chagas disease. Evaluation of potential indicators of parasitological cure following drug therapy.
Projects: Azoles E1224 & Biomarker (Chagas)
Administración Nacional de Laboratorios e Institutos de Salud (ANLIS) (Argentina). Since 2012, DNDi partner for clinical trials for Chagas disease.
B.P Koirala Institute of Health Sciences (Nepal). DNDi partner for clinical trials for VL.
Centro National de Pesquisa em Energia e Materiais (CNPEM) LN BIO (Brazi). Since October 2013, DNDi partner for screening.
Projects: Screening
CNRFP, Centre National de Recherche et de Formation sur le Paludisme (Burkina Faso). Since August 2010, DNDi partner for clinical trials for malaria.
Projects: ASMQ (Malaria)
CSIR, Council of Scientific and Industrial Research (India). Since August 2008, various partnerships for leishmaniasis and HAT through screening and discovery activities of anti-leishmaniasis compounds.
CDRI, Central Drug Research Institute (India). Since June 2007, various discovery partnerships for leishmaniasis and HAT.
Projects: VL-2098 / Nitroimidazole backup (VL)
Fiocruz, Fundaçao Oswaldo Cruz (Brazil). Since 2003, various partnerships through information sharing, discovery, clinical trials, research on malaria (ASMQ) and Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas)
ICDDR, International Centre for Diarrheal Disease Research (Bangladesh). Since November 2009, DNDi partner for clinical trials for VL.
Projects: New VL treatments (Asia) / New VL treatments (Bangladesh)
ICMR, Indian Medical Research Council (India). Since 2006, DNDi partner for clinical trials for VL.
Projects: ASAQ (Malaria) / ASMQ (Malaria) / New VL treatments (Asia)
Instituto de Salud Carlos III (Spain). Since May 2013, scientific collaboration in the field of neglected tropical diseases.
Kala Azar Medical Research Center (India). Since January 2007, DNDi partner for clinical trials for VL.
National Institute for Medical Research (NIMR) (Tanzania). Since 2012, DNDi partner for ASMQ clinical trials for malaria.
Projects: ASMQ (Malaria)
RMRIMS, Rajendra Memorial Research Institute of Medical Sciences (India). DNDi partner for clinical trials for VL.
Projects: New VL treatments (Asia)
State Health Society, Bihar (India). Since 2011, collaboration for the VL Asia Phase IV clinical studies for VL.
Projects: New VL treatments (Asia)
AEDES, consulting firm for Social and Public health sector (Belgium). In 2008, partner for malaria CMC manufacture. Since January 2011, partnership for the technology transfer of ASAQ to Zenufa.
Projects: ASAQ (Malaria)
CEADES, Collective of Applied Studies and Social Development (Bolivia). Since September 2010, DNDi partner for clinical trials of benznidazole against Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas)
Communauté Baptiste du Congo (Democratic Republic of Congo). Since August 2012, DNDi partner for clinical trials of fexinidazole in the field of sleeping sickness.
Projects: Fexinidazole (HAT)
Epicentre, non-for-profit organization which groups health professionals specialized in public health/epidemiology (France). Since November 2005, various partnerships for clinical phases on malaria and HAT.
Projects: ASAQ (Malaria) / ASMQ (Malaria)
IDA Foundation (The Netherlands). Since December 2008, DNDi partner for clinical phase for VL.
Projects: VL-0208
i+solutions (The Netherlands). Continuation of the partnership with IDA Foundation: Leishmaniasis East Africa Platform (LEAP) partner.
Projects: VL-0208 / SSG&PM (VL for Africa)
Médecins Sans Frontières: Since 2003, various partnerships in financing, discovery, and clinical trials.
Projects: ASAQ (Malaria) / Azoles E1224 & Biomarker (Chagas) / Fexinidazole (VL) / HIV/VL / NECT (HAT) / VL-0208 / New VL treatments (Asia) / SSG&PM (VL in Africa)
Microbial Chemistry Research Foundation (Japan) – Since September 2013, DNDi partner for screening.
Projects: Screening
Mundo Sano Foundation (Argentina): Signed a memorandum of undertanding with DNDi on Chagas disease in 2011. Since November 2013, collaborative agreement with DNDi aimed at ensuring availability and access to sustainable and affordable treatments for Chagas disease to both adults and children.
Projects: Paediatric Benznidazole (Chagas)
OTECI, Offre Technique d’Etude et de Coopération Internationale (France). Since January 2008, DNDi partner through technology transfer support for ASMQ (malaria).
Royal Society of Chemistry (UK). Since September 2009, MoU to promote open source discovery.
WHO-TDR: World Health Organization, TDR, Special Programme for Research and Training in Tropical Diseases and co-sponsored by UNICEF, UNDP, the World Bank and WHO. Founding partner since 2003. Various collaboration projects on malaria and kinetoplastids.
Projects: ASAQ (Malaria) / ASMQ (Malaria) / New VL treatments (Asia) / Screening
PDPs/PPPs
FIND, Foundation for Innovative New Diagnostics (Switzerland). Since August 2010, collaboration and material transfer agreement to develop an ELISA-based diagnostic test for leishmaniasis. Since December 2013, MoU for collaboration in the field of neglected tropical diseases.
OWH, Institute for One World Health (USA). Since April 2009, DNDi partner for VL.
Projects: VL-0208 / New VL treatments (Asia) / SSG&PM (VL in Africa)
MMV, Medicines for Malaria Venture (Switzerland). Since September 2004, various partnerships through information sharing, discovery on malaria.
Projects: ASAQ (Malaria) / ASMQ (Malaria) / Screening
NITD Novartis Institute for Tropical Diseases (Singapore). Since April 2007, partnership in discovery on kinetoplastids.
Projects: Screening
TB Alliance: Global Alliance for Tuberculosis Drug Development (USA). Since January 2007, various partnerships through screening and discovery in the field of kinetoplastids.
Projects: Nitroimidazole (Chagas) / Nitroimidazole backup (HAT) / Nitroimidazole backup (VL) / VL-2098 / Screening and Lead Optimization
TI Pharma, public-private partnership (The Netherlands). DNDi partner for discovery activities.
Arba Minch Hospital (Ethiopia). Leishmaniasis East Africa Platform (LEAP) partner. Since April 2005, clinical trial Agreement for VL.
CHUV, Centre Hospitalier Universitaire Vaudois (Switzerland). Since June 2009, technical agreement for discovery.
Projects: ASMQ (Malaria)
Hospital de Ninos Ricardo Gutierrez / Jaime Altcheh (Argentina). Since January 2014, works with DNDi on analysis of sera samples.
Projects: Paediatric Benznidazole (Chagas)
KATH, Komfo Anokye Teaching Hospital (Ghana). Since 2008, DNDi partner for access and data management for ASMQ (malaria).
Projects: ASAQ (Malaria)
Shaheed Suhrawardy Medical College and Hospital (Bangladesh). Since November 2009, DNDi partner for clinical trials for VL.
Projects: New VL treatments (Asia) / New VL treatments (Bangladesh)
Ministries of Health/Governmental organizations
Department of Health (South Africa). Since 2013, donating free treatments for TB/HIV clinical trial. Since April 2014, MoU on improving access to paediatric HIV treatment in South Africa.
Projects: RTV Superbooster for HIV/TB co-infection (Paediatric HIV) / Two “4-in-1” LPV/r based FDC granules (Paediatric HIV) / LPV/r pellets with dual NRTI FDC (Paediatric HIV)
Ministry of Health (Brazil). DNDi partner for clinical trials for VL.
Projects: New VL treatments (Latin America)
Ministry of Health (Cambodia). Since July 2010, DNDi partner for clinical research in the field of malaria.
Projects: ASMQ (Malaria)
Ministry of Health (Ethiopia). Since 2004, Leishmaniasis East Africa Platform (LEAP) partner.
Projects: New VL treatments (Africa)
Ministry of Health (Kenya). DNDi partner for clinical trials for VL.
Projects: New VL treatments (Africa) / SSG&PM (VL in Africa)
Ministry of Health (Rep. Dem. Congo). Since January 2006, various partnerships (financial and clinical trial agreement) in the field of HAT.
Ministry of Health (Uganda). Since 2004, Leishmaniasis East Africa Platform (LEAP) partner.
Projects: New VL treatments (Africa) / SSG&PM (VL in Africa)
CeNDIE, Centro Nacional de Diagnostico e Investigacion de Endemo-epidemias, Ministry of Health, (Argentina).
Projects: Paediatric Benznidazole (Chagas)
Gedarif MoH (Sudan). Leishmaniasis East Africa Platform (LEAP). Since December 2004, various partnerships for clinical trials in the field of leishmaniasis.
Projects: New VL treatments (Africa) / SSG&PM (VL in Africa)
National Trypanosomiasis Control Programmes (Democratic Republic of Congo and Central African Republic). DNDi partners for clinical trials for HAT.
Projects: NECT (HAT)
Contract Research Organizations (CROs)
Accelera (Italy). Since September 2007, works with DNDi on pre-clinical studies.
Advinus Therapeutics (India). Since January 2006, works with DNDi on discovery, pre-clinical, lead optimization and clinical activities. Since November 2013, works with DNDi on CMC and manufacturing activities.
Projects: Nitroimidazole backup (VL) / Oxaborole SCXY-7158 (HAT) / VL-2098
Aptuit (Italy). Since December 2008, provides research services concerning pre-clinical activities as well as CMC and manufacture phases.
Projects: VL-2098
BaseCon (Denmark). Since September 2012, DNDi partner for a pharmacovigilance database on fexinidazole against sleeping sickness. BaseCon is an “in-kind contributor”.
Projects: Fexinidazole (VL)
Bertin Pharma (France). Since March 2011, works with DNDi for capacity strengthening and technology transfer of ASAQ to Zenufa in Tanzania. Since May 2013, works with DNDi on the packaging and shipment of SCYX-7158. Since November 2013, works with DNDi on the preparation of fexinidazole.
Projects: ASAQ (Malaria) / VL-2098 / Oxaborole SCYX-7158 (HAT) / Fexinidazole (HAT)
Calvert Labs (USA). Since June 2012, DNDi partner for pre-clinical phase for topical formulation against cutaneous leishmaniasis.
Cardiabase (France). Since 2011, research service agreement on cardiac safety studies for new chemical entities (NCEs) in clinical stage (Phases I, II/III).
Cardinal System (France). Since January 2004, works with DNDi: clinical activities in the field of malaria and other NTDs.
Projects: Azoles E1224 & Biomarker (Chagas)
Catalent (USA). Since November 2007, works with DNDi: screening, discovery, clinical activities as well as registration and regulatory issues in the field of malaria.
Central Diagnostics (India). Since September 2012, DNDi partner in the field of visceral leishmaniasis.
Centipharm (France). Since November 2007, works with DNDi: CMC/manufacture of fexinidazole for HAT.
Clinwin Research Services (Kenya). Since August 2013, works with DNDi on clinical research project management and monitoring of ASMQ.
Projects: ASMQ (Malaria)
CONICET INGEBI (Argentina). Since October 2010, works with DNDi for clinical phases in the field of Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas) / Paediatric Benznidazole (Chagas)
CoreLab Partners (USA). Since April 2011, works with DNDi for clinical activity for Chagas disease.
Covance (UK). Since December 2013, works with DNDi on pre-clinical activities for VL-2098.
Projects: VL-2098
Creapharm (France). Since March 2014, works with DNDi on CMC activities for fexinidazole for Chagas.
Projects: Fexinidazole (Chagas)
Drugabilis (France). Since 2009, works with DNDi on lead optimization and pre-clinical activities for HAT, VL and filarial diseases. Since May 2013, works with DNDi on small scale tests for filariasis.
Projects: Screening & Lead Optimization / Fexinidazole (HAT) / Oxaborole SCYX-7158 (HAT) / Flubendazole (Filarial diseases) / VL-2098
Endolytics (USA). Since February 2014, works with DNDi on pre-clinical activities for VL 2098.
Projects: VL-2098
Eurofins Optimed (France). Since April 2013, works with DNDi on clinical trial of Oxaborole SCYX-7158. Since June 2013, works with DNDi on activities for the phase 1 study of LPV/r.
Projects: Oxaborole SCYX-7158 (HAT) / Two “4-in-1” LPV/r based FDC granules (Paediatric HIV)
Frontage (USA). Since August 2013, works with DNDi on analysis of E1224 in plasma.
Projects: Azoles E1224 & Biomarker (Chagas)
GVK Biosciences (India). Since October 2006, works with DNDi in the clinical phase for malaria and VL.
Harlan Laboratories (Switzerland). Since 2011, pre-clinical research agreement for Chagas disease.
Huntingdon Life Sciences Limited (UK). Since June 2013, works with DNDi on pre-clinical activities for VL-2098.
Projects: VL-2098
LAT Research (Argentina). Since December 2010, works with DNDi on the clinical studies of benznidazole against Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas)
JSS Medical Research (Canada). Since October 2013, works with DNDi on clinical trials of Anfoleish and fexinidazole for Chagas.
Projects: Anfoleish (CL) / Fexinidazole (Chagas)
NUDFAC, Nucleo de desenvolvimento farmacêutico e cosméticos (Brazil). Since 2012, works with DNDi on data analysis of clinical studies for Chagas disease.
Projects: Azoles E1224 & Biomarker (Chagas) / Paediatric Benznidazole (Chagas)
Patheon (UK). Since 2012, works with DNDi on formulation development and manufacturing for HAT.
Penn Pharmaceuticals Services (UK). Since May 2010, works with DNDi on pre-clinical study (formulation) for HAT.
Projects: Oxaborole SCYX-7158 (HAT)
PhinC Development (France). Since 2010, works with DNDi on Pk/PD and statistics for HAT and, since 2012, on PK/PD analysis for Chagas.
RCTs (France). Since May 2009, works with DNDi on clinical study of NECT for HAT. Since February 2014, works with DNDi on clinical studies for fexinidazole for HAT.
Projects: NECT (HAT) / Fexinidazole (HAT)
Roowin (France). Since 2012, works with DNDi on CMC activities for HAT.
Sandexis LLP (UK). Since August 2012, works with DNDi on research in discovery activities (hit to lead, lead optimization).
Projects: Lead Optimization
Selcia (UK). Since November 2013, works with DNDi on radiosynthesis service for VL-2098.
Projects: VL-2098
Sigma-Aldrich (UK). Since November 2013, works with DNDi on CMC activities for VL-2098.
Projects: VL-2098
SGS (France). Since November 2008, initially worked with DNDi on clinical study of fexinidazole for HAT, subsequently performing bioanalyses.
Theradis Pharma (France). Since June 2012, provides logistical support for the clinical trials of fexinidazole for sleeping sickness.
Projects: Fexinidazole (HAT)
WuXi AppTec (China). Since 2011, lead optimization partner and pre-clinical animal studies and formulation work for HIV paediatric projects.
Projects: Lead Optimization
Please contact us at partnership@dndi.org to propose collaborative projects.